" class="no-js "lang="en-US"> Emma Vaux - Medtech Alert
Friday, August 22, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Emma Vaux

Emma Vaux

About Emma Vaux

Experienced Nephrologist and general physician. Skilled in Quality Improvement, Patient Safety, Medical Education, Professional Standards, Healthcare Management and Research.

Related Story

Diseases

 Avatar-led Programme for Kidney Disease Patients Expands After Successful Pilot | Pharmtech Focus|Avatar-led Programme for Kidney Disease Patients Expands After Successful Pilot | Pharmtech Focus

Avatar-led Programme for Kidney Disease Patients Expands After Successful Pilot

July 27 2021

An avatar-led, interactive, information programme for people with Chronic Kidney Disease (CKD) has been so […]